Literature DB >> 10785597

Trends in mortality from primary liver cancer in Europe.

C La Vecchia1, F Lucchini, S Franceschi, E Negri, F Levi.   

Abstract

Upward trends in incidence and mortality from primary liver cancer have been reported from Japan, the USA and a few European countries. Thus, we systematically reviewed trends in age-standardised death certification rates from primary liver cancer between 1970 and 1996 in 20 European countries providing data for the World Health Organisation database. Overall age-standardised (world population) mortality rates were approximately stable or showed no consistent trends in seven countries, including Bulgaria and Hungary (with exceedingly high rates), Finland, The Netherlands and the UK. Moderate rises were observed in Austria, Germany and Switzerland, and much larger upward trends in France and Italy, particularly for males. Downward trends were observed in both sexes in Belgium, Spain, Ireland, Greece and several Scandinavian countries. The per cent change in rates per year ranged, for males, from -7.4% for Ireland and -5.1% for Spain to +4.4% for Italy and +8.6% for France. Trends were more favourable in women, with 15 out of 20 countries showing downward trends in rates, and moderately more favourable in middle age (45-64 years) and, in major European countries, in young adults (20-44 years of age). In conclusion, trends in liver cancer mortality in Europe are heterogeneous. The fall in mortality in countries like Spain may be largely explained by improvements in the distinction between primary and secondary liver neoplasms, whereas upward trends in Central Europe and Italy are likely to be, at least in part, real. Increases in infection with the hepatitis C virus, and improved and increased searches for liver cancer in cirrhotic patients are two of the likeliest explanations for these observations.

Entities:  

Mesh:

Year:  2000        PMID: 10785597     DOI: 10.1016/s0959-8049(00)00052-6

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  14 in total

Review 1.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

2.  Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma.

Authors:  C Rabe; T Pilz; C Klostermann; M Berna; H H Schild; T Sauerbruch; W H Caselmann
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

3.  Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma.

Authors:  Kazuhiro Kasai; Akira Ushio; Yukiho Kasai; Kei Sawara; Yasuhiro Miyamoto; Kanta Oikawa; Hidekatsu Kuroda; Yasuhiro Takikawa; Kazuyuki Suzuki
Journal:  Int J Clin Oncol       Date:  2010-12-04       Impact factor: 3.402

Review 4.  Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis.

Authors:  Jiangbo Liu; Qingyong Ma; Min Zhang; Xinshuai Wang; Dong Zhang; Wei Li; Fengfei Wang; Erxi Wu
Journal:  Eur J Cancer       Date:  2012-03-27       Impact factor: 9.162

5.  The Incidence of Hepatocellular Carcinoma in Iran from 1996 to 2016: a Systematic Review and Meta-analysis.

Authors:  Soheil Hassanipour; Majid Mohammadzadeh; Fariborz Mansour-Ghanaei; Mohammad Fathalipour; Farahnaz Joukar; Hamid Salehiniya; Elham Abdzadeh; Ali Akbar Samadani; Hossein-Ali Nikbakht; Morteza Arab-Zozani
Journal:  J Gastrointest Cancer       Date:  2019-06

6.  Transcatheter arterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma.

Authors:  Kazuhiro Kasai; Akira Ushio; Kei Sawara; Yasuhiro Miyamoto; Yukiho Kasai; Kanta Oikawa; Hidekatsu Kuroda; Yasuhiro Takikawa; Kazuyuki Suzuki
Journal:  World J Gastroenterol       Date:  2010-07-21       Impact factor: 5.742

7.  Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study.

Authors:  Giuseppe Di Lorenzo; Antonio Rea; Chiara Carlomagno; Stefano Pepe; Giovannella Palmieri; Roberto Labianca; Antonio Chirianni; Alfonso De Stefano; Vincenzo Esposito; Sabino De Placido; Vincenzo Montesarchio
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

8.  Rising costs and hospital admissions for hepatocellular carcinoma in Portugal (1993-2005).

Authors:  Rui Tato Marinho; José Giria; Miguel Carneiro Moura
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

Review 9.  Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

10.  HCC, diet and metabolic factors: Diet and HCC.

Authors:  Maurizio Montella; Anna Crispo; Aldo Giudice
Journal:  Hepat Mon       Date:  2011-03       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.